Dr. Donnellan Discusses Trials in Hematologic Malignancies

William B. Donnellan, MD
Published: Wednesday, Mar 28, 2018



William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

In acute myeloid leukemia (AML), venetoclax (Venclexta) showed a very high response rate when used in combination with a hypomethylating agent in newly-diagnosed patients. There is now a large phase III study launching, which will compare azacitidine either in combination with venetoclax or placebo. The outcome of this trial could potentially change how older patients with AML are treated.

There are several trials ongoing in myelofibrosis, such as the PAC203 study. This study is evaluating pacritinib, a JAK/FLT inhibitor, which has been shown to be effective in patients with myelofibrosis who are resistant or refractory to ruxolitinib (Jakafi). There are some concerns about toxicity, specifically cardiac and hematologic events.
SELECTED
LANGUAGE


William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

In acute myeloid leukemia (AML), venetoclax (Venclexta) showed a very high response rate when used in combination with a hypomethylating agent in newly-diagnosed patients. There is now a large phase III study launching, which will compare azacitidine either in combination with venetoclax or placebo. The outcome of this trial could potentially change how older patients with AML are treated.

There are several trials ongoing in myelofibrosis, such as the PAC203 study. This study is evaluating pacritinib, a JAK/FLT inhibitor, which has been shown to be effective in patients with myelofibrosis who are resistant or refractory to ruxolitinib (Jakafi). There are some concerns about toxicity, specifically cardiac and hematologic events.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x